FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defense 10b5-1(c). See Instr								
1. Name and Address Wesolowski Jo	of Reporting Person*		2. Issuer Name and Ticker or Trading Symbol INTENSITY THERAPEUTICS, INC. [INTS]		tionship of Reporting Perso all applicable) Director	on(s) to Issuer		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/19/2023		Officer (give title below)	Other (specify below)		
	THERAPEUTICS,	INC.	Internit Cr O					
61 WILTON ROA	AD, 3RD FLOOR		4. If Amendment, Date of Original Filed (Month/Day/Year)	, , , , , , , , , , , , , , , , , , , ,				
(Street)				X Form filed by One Reporting Person Form filed by More than One Reporting Per				
WESTPORT	CT	06880			Form filed by More than	One Reporting Person		
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

(2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(111501.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration D	6. Date Exercisable and Expiration Date Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		lerlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Stock Option (right to buy Common Stock)	\$6.43	07/19/2023		A		50,000		(1)	07/19/2033	Common Stock	50,000	\$0	50,000	D		

Explanation of Responses:

1. This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., according to the following schedule: 25% will vest on July 19, 2023, and the remaining 75% will vest in three, equal, annual installments, beginning on July 19, 2024.

/s/ Daniel L. Woodard, Attorney-

in-Fact

** Signature of Reporting Person

Date

07/21/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.